Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with locally advanced or metastatic colorectal cancer, or another type of solid tumour cancer, confirmed through a tissue sample test.
- People whose tumour has tested positive for a specific genetic feature known as MMR deficiency or MSI-H (a marker related to how cancer cells repair their DNA).
- People who have at least one tumour that can be measured on a scan.
- People who are generally active and able to carry out daily activities, with a performance score of 0 or 1 on a standard medical scale (confirm with trial site).
- People who are expected to live for more than 12 weeks.
- People whose blood counts and organ function (such as liver and kidneys) are at adequate levels.
Who may not be able to join:
- People who have taken part in another clinical trial or used an experimental treatment or device within the past 4 weeks, or who have had specific anti-cancer treatment within the past 2 weeks.
- People who have not yet recovered from significant side effects caused by previous cancer treatments.
- People who have previously received a type of cancer treatment known as an immune checkpoint therapy.
- People who have had major surgery within the past 4 weeks.
- People who have another active or progressing cancer that has required treatment within the past 5 years.
- People who have active cancer spread to the brain or the lining of the brain or spinal cord.
- People who have an active autoimmune disease that has required medication to treat.
- People who have a known history of HIV infection.
- People who have signs of a lung condition called interstitial lung disease.
- People who have a known history of significant heart problems.
- People who are unwilling to use highly effective contraception throughout the study.
- People who have other serious or uncontrolled medical conditions that the trial doctor believes would make participation unsafe.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lin Shen, MD, Peking Universtiy Cancer Hospital
Phone: 86-10-88196340
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.